Literature DB >> 32127327

A Systematic Review of Surgical interventions for the Treatment of Bladder Pain Syndrome/Interstitial Cystitis.

Nadir I Osman1, David G Bratt1, Alison P Downey1, Francesco Esperto2, Richard D Inman1, Christopher R Chapple1.   

Abstract

CONTEXT: Bladder pain syndrome/interstitial cystitis (BPS/IC) is a poorly understood chronic debilitating condition. Surgery is reserved for severe refractory cases; however, there is no consensus on patient selection or optimal approach.
OBJECTIVE: To evaluate the evidence relating to the safety and efficacy of surgical interventions for treating BPS/IC. EVIDENCE ACQUISITION: PubMed and Scopus databases were searched for original studies, using keywords "cystectomy", "interstitial cystitis", and "bladder pain syndrome". Articles were reviewed and screened by three independent reviewers. EVIDENCE SYNTHESIS: A total of 450 patients were identified from 20 eligible studies: mean age was 54.5 yr and 90.2% were female. The median duration of symptoms preoperatively was 60 mo (range 9-84), with a mean follow-up of 45.5 mo. A total of 448 patients underwent surgery: subtotal cystectomy with cystoplasty (48.6%), cystectomy and orthotopic neobladder (21.9%), cystectomy and ileal conduit (11.2%), and urinary diversion only (18.3%). Symptomatic improvement occurred in 77.2%, with higher rates in the total cystectomy and orthotopic neobladder group. Thirty-one patients (6.9%) required secondary total cystectomy and/or ileal conduit diversion; 48.4% subsequently improved. Seventeen studies reported 102 complications overall (26.5%). Overall mortality was 1.3%.
CONCLUSIONS: Overall surgical intervention is associated with a 23% risk of failure to improve symptoms. Higher rates of improvement were reported in patients with total cystectomy. Interpretation should be guarded given the small patient number, multiple centres, and variable outcome measurements. There is a need for prospective randomised studies to answer questions regarding patient selection and optimal surgical approach. PATIENT
SUMMARY: In this review, we looked at the outcomes of surgery for treatment-refractory bladder pain syndrome/interstitial cystitis. We found overall symptom improvement in 77.2% of patients with a complication rate of 26.5%. However, there remains a need for further studies of higher quality to identify patients who will have symptom improvement and the best surgical option.
Copyright © 2020 European Association of Urology. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Bladder pain syndrome; Cystectomy; Interstitial cystitis; Reconstructive urology

Mesh:

Year:  2020        PMID: 32127327     DOI: 10.1016/j.euf.2020.02.014

Source DB:  PubMed          Journal:  Eur Urol Focus        ISSN: 2405-4569


  5 in total

Review 1.  Monoclonal Antibody Therapy for the Treatment of Interstitial Cystitis.

Authors:  Ioannis Mykoniatis; Stavros Tsiakaras; Michael Samarinas; Anastasios Anastasiadis; Evangelos N Symeonidis; Petros Sountoulides
Journal:  Biologics       Date:  2022-05-20

2.  Supratrigonal cystectomy and augmentation cystoplasty with ileum or ileocecum in the treatment of ulcerative interstitial cystitis/bladder pain syndrome: a 14-year follow-up.

Authors:  Fabian Queissert; Benedict Bruecher; Arndt van Ophoven; Andres J Schrader
Journal:  Int Urogynecol J       Date:  2022-03-01       Impact factor: 1.932

3.  Protective effect of Aster tataricus extract on NLRP3-mediated pyroptosis of bladder urothelial cells.

Authors:  Xin Wang; Ling Fan; Hao Yin; Yiqun Zhou; Xiaolong Tang; Xiaojun Fei; Hailin Tang; Juan Peng; Xiaoqin Ren; Yi Xue; Chunli Zhu; Jianping Luo; Qinglei Jin; Qingjiang Jin
Journal:  J Cell Mol Med       Date:  2020-10-08       Impact factor: 5.295

Review 4.  Management of Bladder Pain Syndrome (BPS): A Practical Guide.

Authors:  Patrick Juliebø-Jones; Karin M Hjelle; Jannike Mohn; Gigja Gudbrandsdottir; Ingunn Roth; Adeel Asghar Chaudhry; Anne Kvåle Bergesen; Christian Beisland
Journal:  Adv Urol       Date:  2022-01-10

Review 5.  Roles of mesenchymal stem cells and exosomes in interstitial cystitis/bladder pain syndrome.

Authors:  Chao Wen; Liping Xie; Chenxia Hu
Journal:  J Cell Mol Med       Date:  2021-12-24       Impact factor: 5.310

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.